6,392 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,392 shares of the medical research company’s stock, valued at approximately $3,205,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID boosted its position in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares in the last quarter. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth $25,000. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC increased its position in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the period. Finally, Swiss RE Ltd. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $28,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1%

Thermo Fisher Scientific stock opened at $628.69 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm has a market cap of $232.46 billion, a price-to-earnings ratio of 33.82, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. The business’s 50-day moving average price is $545.64 and its 200 day moving average price is $509.60. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 73,493 shares of company stock valued at $43,950,381 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.